AN2 Therapeutics Inc ANTX
News
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease